Jan Weber

List of Publications by Year
in descending order

70	2,391	293460	242451
papers	citations	24 h-index	47 g-index

74	74	74	4219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biogenesis of hepatitis B virus e antigen is driven by transloconâ€associated protein complex and regulated by conserved cysteine residues within its signal peptide sequence. FEBS Journal, 2022, 289, 2895-2914.	2.2	2
2	Decontamination of High-Efficiency Mask Filters From Respiratory Pathogens Including SARS-CoV-2 by Non-thermal Plasma. Frontiers in Bioengineering and Biotechnology, 2022, 10, 815393.	2.0	4
3	Synthesis and in vitro Study of Artemisinin/Synthetic Peroxideâ€Based Hybrid Compounds against SARSâ€CoVâ€2 and Cancer. ChemMedChem, 2022, 17, .	1.6	17
4	A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases. Molecules, 2022, 27, 1894.	1.7	3
5	structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor. Antiviral Research, 2021, 185, 104971.	1.9	5
6	TLR4-Mediated Recognition of Mouse Polyomavirus Promotes Cancer-Associated Fibroblast-Like Phenotype and Cell Invasiveness. Cancers, 2021, 13, 2076.	1.7	3
7	Localization of SARS-CoV-2 Capping Enzymes Revealed by an Antibody against the nsp10 Subunit. Viruses, 2021, 13, 1487.	1.5	12
8	Triterpenoidâ€“PEG Ribbons Targeting Selectivity in Pharmacological Effects. Biomedicines, 2021, 9, 951.	1.4	3
9	Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses. ACS Infectious Diseases, 2021, 7, 471-478.	1.8	22
10	Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties. Journal of Medicinal Chemistry, 2021, 64, 16425-16449.	2.9	13
11	Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication. Pharmaceuticals, 2021, 14, 1111.	1.7	7
12	ATM-Dependent Phosphorylation of Hepatitis B Core Protein in Response to Genotoxic Stress. Viruses, 2021, 13, 2438.	1.5	3
13	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112754.	2.6	21
14	Hepatitis B Core Protein Is Post-Translationally Modified through K29-Linked Ubiquitination. Cells, 2020, 9, 2547.	1.8	13
15	Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Scientific Reports, 2020, 10, 12767.	1.6	14
16	(Iso)Quinolineâ€“Artemisinin Hybrids Prepared through Click Chemistry: Highly Potent Agents against Viruses. Chemistry - A European Journal, 2020, 26, 12019-12026.	1.7	18
17	Multi-sulfonated ligands on gold nanoparticles as virucidal antiviral for Dengue virus. Scientific Reports, 2020, 10, 9052.	1.6	32
18	Polylactic acid as a suitable material for 3D printing of protective masks in times of COVID-19 pandemic. PeerJ, 2020, 8, e10259.	0.9	34

#	Article	IF	Citations
19	LC/MS analysis and deep sequencing reveal the accurate RNA composition in the HIV-1 virion. Scientific Reports, 2019, 9, 8697.	1.6	21
20	Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Research, 2019, 164, 81-90.	1.9	6
21	Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nature Materials, 2018, 17, 195-203.	13.3	331
22	Does BCA3 Play a Role in the HIV-1 Replication Cycle?. Viruses, 2018, 10, 212.	1.5	6
23	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2018, 9, 364.	2.2	26
24	Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART. Viruses, 2018, 10, 154.	1.5	4
25	Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. Scientific Reports, 2018, 8, 10438.	1.6	12
26	Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIÎ² (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology. Journal of Medicinal Chemistry, 2017, 60, 100-118.	2.9	50
27	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Archiv Der Pharmazie, 2017, 350, 1700020.	2.1	5
28	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Research and Therapy, 2017, 14, 15.	0.7	9
29	PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core. PLoS ONE, 2017, 12, e0186982.	1.1	42
30	Purine analogs as phosphatidylinositol 4-kinase IIIÎ² inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2706-2712.	1.0	12
31	Protective hybrid coating containing silver, copper and zinc cations effective against human immunodeficiency virus and other enveloped viruses. BMC Microbiology, 2016, 16, 56.	1.3	76
32	Development of 5â€˜ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clinical Epigenetics, 2016, 8, 19.	1.8	54
33	Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3487-3490.	1.0	4
34	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. PLoS ONE, 2016, 11, e0156063.	1.1	35
35	Synthesis and biological profiling of 6- or 7-(het)aryl-7-deazapurine 4â€²-C-methylribonucleosides. Bioorganic and Medicinal Chemistry, 2015, 23, 7422-7438.	1.4	15
36	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor. Nature Communications, 2015, 6, 6461.	5.8	25

#	Article	IF	Citations
37	Highly Selective Phosphatidylinositol 4-Kinase IIIÎ² Inhibitors and Structural Insight into Their Mode of Action. Journal of Medicinal Chemistry, 2015, 58, 3767-3793.	2.9	54
38	Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy. PLoS ONE, 2014, 9, e104512.	1.1	12
39	Highly Functionalized and Potent Antiviral Cyclopentane Derivatives Formed by a Tandem Process Consisting of Organometallic, Transitionâ€Metalâ€Catalyzed, and Radical Reaction Steps. Chemistry - A European Journal, 2014, 20, 10298-10304.	1.7	15
40	Synthesis and biological activity of benzo-fused 7-deazaadenosine analogues. 5- and 6-substituted 4-amino- or 4-alkylpyrimido[4,5-b]indole ribonucleosides. Bioorganic and Medicinal Chemistry, 2013, 21, 5362-5372.	1.4	26
41	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Journal of Clinical Microbiology, 2013, 51, 1517-1527.	1.8	18
42	Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors. PLoS ONE, 2013, 8, e65631.	1.1	10
43	Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism. PLoS ONE, 2012, 7, e49602.	1.1	78
44	Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. Antiviral Research, 2011, 91, 94-98.	1.9	9
45	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3â€²Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 3729-3742.	1.4	23
46	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. Antimicrobial Agents and Chemotherapy, 2011, 55, 3645-3645.	1.4	0
47	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. Antimicrobial Agents and Chemotherapy, 2011, 55, 1403-1413.	1.4	29
48	Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs. Journal of Clinical Microbiology, 2009, 47, 2232-2242.	1.8	13
49	Current tests to evaluate HIV-1 coreceptor tropism. Current Opinion in HIV and AIDS, 2009, 4, 136-142.	1.5	40
50	Viral Drug Resistance and Fitness. Advances in Pharmacology, 2008, 56, 257-296.	1.2	30
51	Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 255-262.	0.9	6
52	Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals. Current HIV Research, 2008, 6, 531-538.	0.2	74
53	HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Reviews, 2008, 10, 172-89.	0.5	23
54	Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. Current Opinion in HIV and AIDS, 2007, 2, 81-87.	1.5	7

#	Article	IF	Citations
55	The impact of viral and host elements on HIV fitness and disease progression. Current HIV/AIDS Reports, 2007, 4, 36-41.	1.1	5
56	Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. Journal of Virological Methods, 2006, 136, 102-117.	1.0	47
57	HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Reviews, 2006, 8, 60-77.	0.5	30
58	Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation. Journal of Clinical Microbiology, 2005, 43, 1395-1400.	1.8	76
59	Can HIV-1 superinfection compromise antiretroviral therapy?. Aids, 2004, 18, 131-134.	1.0	16
60	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. Journal of General Virology, 2003, 84, 2217-2228.	1.3	37
61	Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. Journal of Virology, 2003, 77, 9069-9073.	1.5	77
62	Human epithelial Î²-defensins 2 and 3 inhibit HIV-1 replication. Aids, 2003, 17, F39-F48.	1.0	388
63	Role of Baseline pol Genotype in HIV-1 Fitness Evolution. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 448-460.	0.9	25
64	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. Journal of Virology, 2002, 76, 10546-10552.	1.5	40
65	Unusual Binding Mode of an HIV-1 Protease Inhibitor Explains its Potency against Multi-drug-resistant Virus Strains. Journal of Molecular Biology, 2002, 324, 739-754.	2.0	46
66	Secreted aspartic proteases of Candida albicans , Candida tropicalis , Candida parapsilosis and Candida lusitaniae. FEBS Journal, 2001, 268, 2669-2677.	0.2	105
67	A Picomolar Inhibitor of Resistant Strains of Human Immunodeficiency Virus Protease Identified by a Combinatorial Approach. Archives of Biochemistry and Biophysics, 2000, 382, 22-30.	1.4	18
68	Peptide Inhibitors of Aspartic Proteinases with Hydroxyethylene Isostere Replacement of Peptide Bond. II. Preparation of Pseudotetrapeptides Derived from Diastereoisomeric 5-Amino-2-benzyl-4-hydroxy-6-phenylhexanoic Acids. Collection of Czechoslovak Chemical Communications, 1998, 63, 541-548.	1.0	3
69	Potency Comparison of Peptidomimetic Inhibitors against HIV-1 and HIV-2 Proteinases: Design of Equipotent Lead Compounds. Archives of Biochemistry and Biophysics, 1997, 341, 62-69.	1.4	18
70	Configurations of Diastereomeric Hydroxyethylene Isosteres Strongly Affect Biological Activities of a Series of Specific Inhibitors of Human-Immunodeficiency-Virus Proteinase. FEBS Journal, 1997, 250, 559-566.	0.2	25